Clinical trials
Hepatitis C trials in the Netherlands
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
50 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 1 |
| 2003 | 1 |
| 2005 | 3 |
| 2006 | 3 |
| 2007 | 5 |
| 2008 | 4 |
| 2009 | 2 |
| 2010 | 2 |
| 2011 | 6 |
| 2012 | 9 |
| 2013 | 3 |
| 2014 | 1 |
| 2015 | 2 |
| 2016 | 2 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 2 |
| 2021 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 40 |
| Terminated | 4 |
| Unknown status | 2 |
| Withdrawn | 2 |
| Active, not recruiting | 1 |
| Enrolling by invitation | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Foundation for Liver Research | 7 |
| Bristol-Myers Squibb | 6 |
| Gilead Sciences | 6 |
| Radboud University Medical Center | 6 |
| Vertex Pharmaceuticals Incorporated | 4 |
| Erasmus Medical Center | 3 |
| UMC Utrecht | 3 |
| Hoffmann-La Roche | 2 |
| Janssen R&D Ireland | 2 |
| Santaris Pharma A/S | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Hepatitis C | 50 |
| Hepatitis C, Chronic | 7 |
| Bronchiolitis Obliterans Syndrome | 5 |
| Acquired Immunodeficiency Syndrome | 3 |
| Deglutition Disorders | 2 |
| Diabetes Mellitus | 2 |
| Fibrosis | 2 |
| Acidosis, Lactic | 1 |
| Cardiovascular Diseases | 1 |
| Coinfection | 1 |
Trials
Showing 1 to 25 of 50. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.